Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Provectus Biopharmaceuticals, Inc. (OTC: PVCT).

Full DD Report for PVCT

You must become a subscriber to view this report.


Recent News from (OTC: PVCT)

PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATION AT ESMO 2018 CONGRESS
FOR IMMEDIATE RELEASE KNOXVILLE, TN, July 24, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing clinical trial of PV-10 for the treatment of symptomatic metastatic neuroendocrine tumors of the liver ( NCT02693067 ) will be prese...
Source: GlobeNewswire
Date: July, 24 2018 07:00
PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
KNOXVILLE, TN, July 10, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting , held in Munich, Germany from June 28-29. The presentation, entitled “Current Clinica...
Source: GlobeNewswire
Date: July, 10 2018 08:00
PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE
FOR IMMEDIATE RELEASE KNOXVILLE, TN, June 19, 2018 (GLOBE NEWSWIRE) -- Provectus today announced that the Indian Patent Office (IPO) has granted the Company’s patent application for the synthetic process used to produce the active pharmaceutical ingredient (API) in PV-10, which i...
Source: GlobeNewswire
Date: June, 19 2018 09:00
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE PV-10 ABSTRACT AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
FOR IMMEDIATE RELEASE Research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center identifies PV-10 activity, mechanisms of action, drug synergy, and in vivo activity   Preclinical data support advan...
Source: GlobeNewswire
Date: May, 17 2018 08:00
PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
FOR IMMEDIATE RELEASE Data presentation planned for first half of 2019 KNOXVILLE, TN, May 07, 2018 (GLOBE NEWSWIRE) -- Provectus today announced the completion of enrollment of 24 patients with metastatic melanoma into the Phase 1b portion of the Company’s Phase 1b/2 study ...
Source: GlobeNewswire
Date: May, 07 2018 08:00
STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE
FOR IMMEDIATE RELEASE Combinations with PV-10 included + anti-CTLA-4; + anti-PD-1; + anti-PD-L1; and, + anti-PD-1 + Treg depletion   Data provided basis for ongoing Phase 1b/2 study of PV-10 in combination with KEYTRUDA® for Stage IV melanoma ( NCT02557321 )  ...
Source: GlobeNewswire
Date: April, 30 2018 09:00
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
FOR IMMEDIATE RELEASE Preclinical pediatric cancer research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center KNOXVILLE, TN & NEW YORK, NY, April 25, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharma...
Source: GlobeNewswire
Date: April, 25 2018 16:00
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair   Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio....
Source: GlobeNewswire
Date: April, 24 2018 07:00
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com ) (“Provectus” or the “Company”), a clinical-stage biotechnology company developing PV-10 as the first small mol...
Source: GlobeNewswire
Date: April, 19 2018 06:00
Provectus awarded patents in Japan and Europe covering PV-10
Provectus Biopharmaceuticals (NYSEMKT: PVCT ) announces that the Japan Patent Office has granted and the European Patent Office allowed its patent application for the combination of PV-10 with systemic immunomodulatory therapy. More news on: Provectus Biopharmaceuticals, Inc., Pfizer Inc...
Source: SeekingAlpha
Date: April, 18 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.056750.060.06350.056240,674
2018-12-130.06150.0630.0660.0615180,704
2018-12-120.05310.06110.0670.0531597,385
2018-12-110.0640.062670.06680.0611224,785
2018-12-100.0650.063050.0660.061170,295

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14187,215240,67477.7878Short
2018-12-1376,119180,70442.1236Short
2018-12-12224,202519,38543.1668Short
2018-12-11155,685224,78569.2595Short
2018-12-1047,850170,29528.0983Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PVCT.


About Provectus Biopharmaceuticals, Inc. (OTC: PVCT)

Logo for Provectus Biopharmaceuticals, Inc. (OTC: PVCT)

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV , is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH , its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase trials of PV as a therapy for metastatic melanoma, and of PH as a topical treatment for psoriasis. In addition, Provectus has begun a Phase trial as a therapy for metastatic melanoma. Information about these and the Company s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company s website at www.provectusbio.com.

 

Contact Information

 

 

Current Management

  • Timothy C. Scott, Ph.D. / President, Principal Executive Officer
  • Eric Wachter, Ph.D. / CTO
  • Dominic Rodrigues / Chairman, Independent Director
  • Bruce Horowitz / Independent Director
  • Jan E. Koe /
  • Eric Wachter, Ph.D. /

Current Share Structure

  • Market Cap: $27,433,144 - 03/09/2018
  • Authorized: 1,000,000,000 - 03/09/2018
  • Issue and Outstanding: 378,388,190 - 03/09/2018
  • Float: 75,807,312 - 06/30/2016

 


Recent Filings from (OTC: PVCT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 06 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 12 2017

 

 


Daily Technical Chart for (OTC: PVCT)

Daily Technical Chart for (OTC: PVCT)


Stay tuned for daily updates and more on (OTC: PVCT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PVCT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PVCT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PVCT and does not buy, sell, or trade any shares of PVCT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/